Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 7;15(1):156. doi: 10.1186/s12931-014-0156-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Qi et al.; licensee BioMed Central Ltd. 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

The expression of AMPK in muscle tissue was decreased in COPD model rats, and AICAR or resveratrol treatment recovered AMPK expression in COPD model rats. (A) Sample blots of AMPK and β-actin. Normalized muscle AMPK mRNA (B; Control: n = 14; COPD/saline: n = 12, 0.35 ± 0.04; COPD/AICAR, n = 14, 1.50 ± 0.12; COPD/Resveratrol, n = 12, 0.96 ± 0.05; ***F _{1, 25} = 68.31, p < 0.001 comparing the control group to the COPD/saline group; **F _{1, 27} = 11.89, p = 0.002 comparing the control group to the COPD/AICAR group; ###F _{1, 23} = 74.98, p < 0.001 comparing COPD/saline to COPD/resveratrol; ###F _{1, 25} = 60.98, p < 0.001 comparing COPD/saline to COPD/AICAR group). Normalized muscle AMPK protein (C; Control: n = 14; COPD/saline: n = 12, 0.32 ± 0.03; COPD/AICAR, n = 14, 0.96 ± 0.04; COPD/resveratrol, n = 12, 0.66 ± 0.01; ***F _{1, 25} = 66.17, p < 0.001 comparing the control group to the COPD/saline group; ***F _{1, 25} = 25.21, p < 0.001 comparing the control group to the COPD/resveratrol group; n.s. F _{1, 27} = 0.16, p = 0.70 comparing the control group to the COPD/AICAR; ###F _{1, 25} = 31.52, p < 0.001 comparing COPD/saline to COPD/AICAR; ###F _{1, 23} = 24.58, p < 0.001 comparing COPD/saline to COPD/resveratrol group. n.s. (not significant). Normalized muscle p-AMPK protein (D; Control: n = 6; COPD/saline: n = 6, 0.58 ± 0.14; COPD/AICAR, n = 6, 1.26 ± 0.30; COPD/resveratrol, n = 6, 1.29 ± 0.30; * F _{1, 11} = 5.1, p < 0.05 comparing the control group to the COPD/saline group; ###F _{2, 17} = 15.15, p < 0.001 comparing COPD/saline to COPD/AICAR and COPD/resveratrol. n.s. F _{2, 17} = 0.093 comparing the control group to the COPD/resveratrol group and COPD/resveratrol. n.s. (not significant).